Nov 22, 2024
Tony Goodman is the Chief Operating Officer at Adial Pharmaceuticals, which is developing a personalized therapy for alcohol use disorder based on a genetic biomarker. This unique approach combines the therapeutic AD04 with the biomarker AG Plus to identify a specific AUD patient population that responds well to this...
Nov 22, 2024
Tony Goodman is the Chief Operating Officer at Adial Pharmaceuticals, which is developing a personalized therapy for alcohol use disorder based on a genetic biomarker. This unique approach combines the therapeutic AD04 with the biomarker AG Plus to identify a specific AUD patient population that responds well to this...
Aug 20, 2024
Professor Sir Peter Donnelly, Founder and CEO of Genomics plc, aims to use cutting-edge polygenic risk scores to identify inherited DNA mutations and genetic predispositions that could lead to common diseases. In partnership with the MassMutual life insurance company, Genomics offers a voluntary test that...
Aug 20, 2024
Professor Sir Peter Donnelly, Founder and CEO of Genomics plc, aims to use cutting-edge polygenic risk scores to identify inherited DNA mutations and genetic predispositions that could lead to common diseases. In partnership with the MassMutual life insurance company, Genomics offers a voluntary test that...
Jul 15, 2024
Dr. Steve Goldberg, physician and Senior Clinical Advisor at DecisionRx, and Dr. Jamie Wilkey, pharmacist and expert on medication therapy optimization, explain that medications are the fourth leading cause of death in the country. They emphasize the need to consider genetic information and pharmacogenomics to design...